STUDY SEARCH RESULTS

1 study found for your search request:  4280A-010

Study of Favezelimab Coformulated with Pembrolizumab (MK-4280A) in Participants with Selected Solid ...
Condition: Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT06036836
Status: Completed




Copyright © 2026 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  Consumer Health Data Privacy Policy  Your Privacy Choices   Accessibility  U.S. Corporate Site